Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease: The FIDELITY Pre-Specified Pooled Analysis

ISN INTERNATIONAL SOCIETY OF NEPHROLOGY

Methods and Cohort

Pre-specified pooled efficacy and safety analysis

FIDELIO and FIGARO RCT cohorts (n= 13 026)

✓ Age ≥18 years
✓ Type 2 DM and CKD
  • mean eGFR 57.6mL/min/1.7m2
  • median UACR 515 mg/g
✓ on maximum tolerated RASi

Finerenone vs placebo

Key Outcomes

	Placebo	Finerenone	HR (95% CI)
Kidney composite efficacy outcome	7.1%	5.5%	**0.77** (0.67–0.88) *p= 0.0002*
Sustained eGFR reduction ≥57%	5.5%	3.9%	**0.70** (0.60-0.83) p<0.0001
Kidney failure*	4.6%	3.9%	**0.84** (0.71-0.99) *p=0.03*
Renal death	<0.1%	0.1%	**0.53** (0.10-2.91) *p= 0.46*
Safety			
SAE*	33.7%	31.6%	
Hyperkalemia	5.9%	12.0%	

*Kidney failure = end-stage kidney disease (ESKD) or a sustained decrease in eGFR to <15 mL/min/1.73 m2

*Serious adverse event

Conclusion: Finerenone reduced the risk of clinically important kidney outcomes vs. placebo across the spectrum of CKD in patients with type 2 diabetes.